Caas Capital Management LP Moderna, Inc. Put Options Transaction History

Caas Capital Management LP

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Oct 28, 2024	BUY	$63.64 - $125.14 $776,408 - $1.53 Million	12,200 Added 90.37%	25,700 $1.72 Million
Q2 2024 Jul 15, 2024	SELL	$101.21 - $166.61 $2.15 Million - $3.53 Million	-21,200 Reduced 61.1%	13,500 $1.6 Million
Q1 2024 Apr 26, 2024	BUY	$85.37 - $115.44 $2.96 Million - $4.01 Million	34,700 New	34,700 $3.7 Million
Q1 2023 May 15, 2023	BUY	$135.66 - $197.02 $2.86 Million - $4.16 Million	21,100 New	21,100 $3.24 Million
Q3 2022 Nov 14, 2022	SELL	$118.07 - $194.18 $8.96 Million - $14.7 Million	-75,900 Reduced 69.76%	32,900 $3.89 Million
Q2 2022 Aug 15, 2022	BUY	$117.13 - $176.59 $12.3 Million - $18.5 Million	104,800 Added 2620.0%	108,800 $15.5 Million
Q1 2022 May 13, 2022	SELL	$126.46 - $235.05 $1.39 Million - $2.59 Million	-11,000 Reduced 73.33%	4,000 $689,000
Q3 2021 Nov 15, 2021	SELL	$221.9 - $484.47 $6.1 Million - $13.3 Million	-27,500 Reduced 64.71%	15,000 $5.77 Million
Q1 2021 May 17, 2021	SELL	$109.18 - $185.98 $23.8 Million - $40.5 Million	-218,000 Reduced 83.69%	42,500 $5.57 Million
Q4 2020 Feb 12, 2021	BUY	$65.74 - $169.86 $17.1 Million - $44.2 Million	260,500 New	260,500 $27.2 Million

953

240M

10.6M

18.7M

Ticker MRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 391,200,000
Market Cap $15.4B
Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Caas Capital Management LP with notifications on news.